TY - JOUR T1 - Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.180456 SP - jrheum.180456 AU - Jaime Guzman AU - Andrew Henrey AU - Thomas Loughin AU - Roberta A. Berard AU - Natalie J. Shiff AU - Roman Jurencak AU - Adam M. Huber AU - Kiem Oen AU - Kerstin Gerhold AU - Brian M. Feldman AU - Rosie Scuccimarri AU - Kristin Houghton AU - Gaëlle Chédeville AU - Kimberly Morishita AU - Bianca Lang AU - Paul Dancey AU - Alan M. Rosenberg AU - Julie Barsalou AU - Alessandra Bruns AU - Karen Watanabe Duffy AU - Susanne Benseler AU - Ciaran M. Duffy AU - Lori B. Tucker AU - the ReACCh-Out Investigators Y1 - 2019/01/15 UR - http://www.jrheum.org/content/early/2019/01/11/jrheum.180456.abstract N2 - Objective To estimate the probability of early remission with conventional treatment for each child with juvenile idiopathic arthritis (JIA). Children with a low chance of remission may be candidates for initial treatment with biologics or triple disease-modifying antirheumatic drugs (DMARD). Methods We used data from 1074 subjects in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) cohort. The predicted outcome was clinically inactive disease for ≥ 6 months starting within 1 year of JIA diagnosis in patients who did not receive early biologic agents or triple DMARD. Models were developed in 200 random splits of 75% of the cohort and tested on the remaining 25% of subjects, calculating expected and observed frequencies of remission and c-index values. Results Our best Cox logistic model combining 18 clinical variables a median of 2 days after diagnosis had a c-index of 0.69 (95% CI 0.67–0.71), better than using JIA category alone (0.59, 95% CI 0.56–0.63). Children in the lowest probability decile had a 20% chance of remission and 21% attained remission; children in the highest decile had a 69% chance of remission and 73% attained remission. Compared to 5% of subjects identified by JIA category alone, the model identified 14% of subjects as low chance of remission (probability < 0.25), of whom 77% failed to attain remission. Conclusion Although the model did not meet our a priori performance threshold (c-index > 0.70), it identified 3 times more subjects with low chance of remission than did JIA category alone, and it may serve as a benchmark for assessing value added by future laboratory/imaging biomarkers. ER -